Moderna (MRNA) Expected to Announce Earnings on Friday

robot
Abstract generation in progress

Moderna (MRNA) is slated to release its Q1 2026 earnings before market open on Friday, May 1st, with analysts forecasting a loss of ($2.03) EPS and $251.0 million in revenue. The company faces ongoing financial challenges, including negative margins and projected yearly losses, despite potential boosts from EU approval of mCOMBRIAX and a Phase 3 bird-flu vaccine trial. Recent insider selling and past U.S. funding cuts for its bird-flu program are noted headwinds.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin